Özet:

Tuberculosis (TB) is a chronic, granulomatous bacterial disease with different clinical manifestations caused by Mycobacterium tuberculosis (M. tuberculosis). TB continues to be a public health problem that still maintains its importance today. Given the recent years of co-infection with HIV/AIDS and multidrug-resistant (MDR) cases, treatment for TB disease is available in combination with multiple anti-TB drugs for at least six months. Current first-line (primary) treatments for TB, administration of a combination of isoniazid (INH), rifampicin (RIF), pyrazinamide(PZA), and ethambutol(EMB) during the first two months and then based on INH and RIF treatment for a duration of more than four to seven months. In the treatment of TB, with prolonged use of anti-TB drugs, the emergence and spread of MDR and extensive drug-resistant (XDR) M. tuberculosis strains present challenges in treating TB. In this review, it was aimed to mention the general properties of first and second-line anti-TB drugs used in the treatment of TB.

Anahtar Kelimeler: